Disease · MONDO_0027766

generalized lipodystrophy

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. generalized lipodystrophy. Diseases, record MONDO_0027766. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0027766

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: generalized lipodystrophy; Open Targets
Open Targets ID: MONDO_0027766; Open Targets
Other names: Generalised lipodystrophy, Lipodystrophy, generalised, Lipodystrophy, generalized, complete generalised lipodystrophy, complete generalized lipodystrophy; Open Targets
Disease Ontology: DOID:0080298; Disease Ontology
NCI Thesaurus: C131815; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 2 of its 2 drugs, from ClinicalTrials.gov; Open Targets

Drugs2

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
MIBAVADEMAB	CHEMBL4650509	Antibody	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
METRELEPTIN	CHEMBL2107857	Protein	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets

Targets1

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes
LEPR	Leptin receptor	2	Leptin receptor agonist	Phase 3	https://conductscience.org/library/genes/3953

Source Drugs and targets

Trials5

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT04159415	Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy	Phase 2	16	2025-02-25	Generalized Lipodystrophy	MIBAVADEMAB	Its record names the disease	ClinicalTrials.gov
NCT07220785	Efficacy and Safety of Mibavademab in Adult and Pediatric Patients With Generalized Lipodystrophy	Phase 3	28		Generalized Lipodystrophy	MIBAVADEMAB	Its record names the disease	ClinicalTrials.gov
NCT02262832	Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy	Phase 3	24		Lipodystrophy, Diabetes, Hyperlipidemia	METRELEPTIN	Its record names the disease	ClinicalTrials.gov
NCT06548100	A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)	Phase 3	9		Generalized Lipodystrophy	MIBAVADEMAB	Its record names the disease	ClinicalTrials.gov
NCT06502990	Open-label Study to Evaluate Metreleptin in Children Under 6 Years of Age With Generalised Lipodystrophy	Phase 3	1		Generalized Lipodystrophy	METRELEPTIN	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials1

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial
Treatment Sequence A vs Treatment Sequence B: Number of Participants With Anti-drug Antibodies (ADA) to REGN4461	0 of 8	0 of 8	16	NCT04159415

Source Trial comparisons

Papers from its trials1

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it
28324110	DERIVED	1

Source PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0027766

GET https://conductscience.org/api/diseases/v1/MONDO_0027766/drugs

API reference For AI assistants